A recap of the top women's health headlines from October 2026, including FDA approval of pritelivir for refractory HSV, ACOG's new menopause guideline, and more.
|Podcasts|February 28, 2022
Caring for women who are or have been incarcerated: contraception, sexual health, and trauma-informed care
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Advertisement
Advertisement
Related to this article
Distress, not low libido alone, defines HSDD, which requires a biopsychosocial evaluation, according to Holly N. Thomas, MD, MS.
Soma Mandal, MD, MSCP, says removing MHT boxed warnings is overdue but calls for transparency on the FDA's product-specific rationale.
CMS' proposed G-codes, which experts stated would cause confusion in combination with the AMA's proposed codes, were not included in the final fee schedule for 2027, according to ACOG.
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
Samples from a large UK screening trial supported validation of the investigational Evident ovarian cancer test, according to Dawn Mattoon, PhD.
Lisa Taylor-Swanson, PhD, on a pilot in which integrative group medical visits improved menopause symptoms, knowledge, and self-efficacy.
Peter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Reactions to FDA's boxed warning removals for menopausal hormone therapy
2
Centers for Medicare, Medicaid Services includes AMA's obstetric codes in 2027 fee schedule
3
Top headlines in women's health from October 2026
4
FDA grants accelerated approval to DNA immunotherapy for adult recurrent respiratory papillomatosis
5